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1. Introduction  
Sarcoidosis is a common multisystem granulomatous disease of unknown etiology. 
Overall the prognosis is not necessarily deleterious because organ involvement is usually 
asymptomatic except for ocular or cutaneous involvements and the disease is often self-
limiting. Cardiac Sarcoidosis is rare (5%) but once the heart is involved, the patient’s 
prognosis is poor because of the development of fatal arrhythmias, atrioventricular 
conduction disturbance or refractory congestive heart failure (Newman et al., 1997). 
Despite advanced research, a clear cause and pathogenesis for sarcoidosis remains 
unknown. Sarcoidosis is thought to be caused by an abnormal, exaggerated response of 
the immune system.  Infectious agents such as Propionibacterium acnes, Mycobacteria 
suspected of causing sarcoidosis (Nishiwaki et al., 2004; Hance, 1998) , but The American 
Thoracic Society's wide-ranging Statement on Sarcoidosis suggested that there is no clear 
evidence of an infectious agent causing sarcoidosis. Genetic factors such as the human 
leucocyte antigens (specifically HLA-DRB1) may be a predisposition for sarcoidosis 
(Maliark et al., 1998), but not the only cause.  Currently, sarcoidosis is considered to be 
caused by multiple factors. 
2. Diagnostics 
There are no specific symptoms or signs of CS. Clinical manifestations such as dyspnea, 
palpitations, syncope are often associated with arrhythmias or heart failure. There is no 
golden standard for diagnosis of CS. Since 1993, the Japanese Ministry of Health and 
Welfare (JMHW) guidelines (Hiraga et al., 1993) have been widely used as the reference 
standard (table 1).  
Endomyocardial biopsy is specific but it shows noncaseating granulomas no more than 25% 
of CS (Uemura et al., 1999; Ardehali et al., 2005). Diagnosis of CS is often made by 
combination of cardiac abnormality and pathology of other organs.  
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1     Histologic diagnosis group: endomyocardial biopsy demonstrates epithelioid 
granulomata without caseating granulomata.  
2     Clinical diagnosis group: in patients with histologic diagnosis of extracardiac 
sarcoidosis, cardiac  sarcoidosis is suspected when “a” and at least one of criteria “b” to 
“d” is present, and other etiologies such as hypertension and coronary artery disea have 
been excluded:  
a.    Complete RBBB, left-axis deviation, AV block, VT, PVC, or pathological Q or ST-T 
change on resting or ambulatory electrocardiogram.  
b.    Abnormal wall motion, regional wall thinning, or dilation of the left ventricle. 
c.    Perfusion defect by 201thallium-myocardial scintigraphy or abnormal accumulation 
by 67Ga-citrate or  99mTc-PYP myocardial scintigraphy.    
d.    Abnormal intracardiac pressure, low cardiac output, or abnormal wall motion or 
depressed ejection fraction of the left ventricle.       
AV atrioventricular; LBBB  left bundle branch block; PVC  premature ventricular 
contraction; RBBB  right bundle branch block; VT  ventricular tachycardia.   
Table 1. Modified Guidelines for the Diagnosis of Cardiac Sarcoidosis Based on the Study 
Reporton Diffuse Pulmonary Diseases From the Japanese Ministry of Health and Welfare, 
1993.  
2.1 Electrocardiography 
Electrocardiographic conduction abnormalities, atorioventricular block (AVB) or bundle 
branch block (BBB) are well known as the characteristic manifestation of CS. These 
manifestations have been detected in less than 5% of patients with sarcoidosis (Silverman et 
al., 1978). Nevertheless, in autopsy studies, cardiac involvements have been found in 20% to 
58% of the cases, indicating latent CS does exist in a larger part of the sarcoidosis patients, 
even if routine electrocardiogram (ECG) shows no abnormal findings (Loncope et al., 1952; 
Iwai et al., 1994; Bargout et al. 2004). Previously, we reported the results of signal averaged 
electrocardiography (SAECG) in 10 cardiac sarcoidosis patients, 52 pulmonary sarcoidosis 
patients with normal ECG, and 52 normal controls (Yodogawa et al., 2007). We found that 
late potentials (LP) were positive in 80% of cardiac sarcoidosis patients, 46.2% in pulmonary 
sarcoidosis patients, and 5.8% in normal control (P < 0.0001). These results suggested that 
latent cardiac abnormality may exist in sarcoidosis patients even if ECG is normal. In a 
similar point of view, there is increasing concern about “subclinical” cardiac sarcoidosis. 
Soejima et al stated that many patients who have cardiac sarcoidosis are asymptomatic, and 
Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) are useful 
for early detection of cardiac abnormality (Soejima & Yada, 2009). 
2.2 Echocardiography 
In the early stage, regional wall thickness caused by granulomatous infiltration may be 
noted (Yazaki et al., 1998; Matsumori et al., 2000). Later, myocardial scar occurred as the 
result of healed sarcoid granulomas. In the progressed stage, thinning of myocardium, wall 
motion abnormality, and sometimes aneurysms (Sato et al., 2010) are seen. Valantine et al. 
reported that thinning at the base of the intra-ventricular septum is pathognomonic for CS 
(Valantine et al., 1987). However, the sensitivity is reported to be relatively low (20%) 
(Uemura et al., 2005).  
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2.3 Gallium-67 scintigraphy 
Gallium-67 scintigraphy has been widely used in diagnosis and management of CS. Gallium 
uptake in the heart indicates active inflammation, which is a useful finding in predicting the 
response to corticosteroid therapy (Okayama et al. 1995).  Futamatsu et al. recently reported 
that gallium-67 scintigraphy is useful for evaluation of CS with ventricular tachycardia (VT) 
(Futamatsu et al., 2006). According to the study, accumulation of gallium-67 in the heart at the 
time of diagnosis was detected more frequently in the VT group than in the non-VT group 
(14.3 vs 71.4%, P < 0.05). Thus, Gallium-67 uptake is highly specific to inflammatory disease 
and a useful for detection of disease activity of cardiac sarcoidosis. Meanwhile, the main 
disadvantage is lack of sensitivity (20%, 36%) (Okayama et al., 1995; Kiuchi et al., 2007). 
2.4 Positron Emission Tomography (PET)   
PET is noninvasive imaging technique using small amounts of radioactive positrons for 
measuring the metabolic activity of cells in the human body. Fluorine-18 fluorodeoxyglucose-
(18F-FDG) is accumulated by inflammatory cells, and widely used radiotracer for PET imaging 
studies. Yamagishi et al. reported a significantly higher sensitivity of 18F-FDG uptake for 
detection of CS compared with that of Gallium-67 uptake (Yamagishi et al., 2003). They also 
showed improvement of 18F-FDG uptake after corticosteroid therapy. Hence, FDG-PFT is 
considered to be useful not only for detection but therapeutic monitoring of cardiac 
involvement. The biggest advantage of PET is its high sensitivity (87.5%, 100%, and 100%), but 
the specificity is obscure (38.5%, 81.5%, and 90.9%) (Ohira et al., 2008; Ishimaru et al., 2005; 
Okumura et al., 2004). This may be due to the possibility of detecting subclinical CS or natural 
accumulation with interindividual variability.  
2.5 Magnetic Resonance Imaging (MRI) 
Cardiac MRI is a noninvasive diagnostic testing to detect structural abnormalities. Increased 
signal intensity of T2-weighted images is considered to indicate active inflammation area, and 
Gadolinium-DTPA enhanced the detection of the region. Cardiac MRI has been reported to be 
useful for detecting areas of inflammation associated with sarcoid granulomas (Shimada et al., 
2001). Several reports have shown high sensitivity (100%) and specificity (78% and 100%) for 
diagnosis of CS (Smedema et al., 2005; Tadamura et al., 2005). However, one of the main 
disadvantages is that MRI is not recommended for patients with implantable cardiac devices, 
such as pacemaker, or implantable cardioverter-defibrillator (ICD). 
3. Treatment 
In patients with definite diagnosis of CS, corticosteroid therapy should be considered. In 
general, the initial dosage is 30 mg/day of prednisone or its equivalent on alternate days, 
which was tapered over a period of 6 months to a maintenance dosage of 5-10 mg/day. 
Initiation of corticosteroid therapy is reported to preserve LV function and improve outcomes 
(Yazaki et al., 2001; Chiu et al., 2005). Concerning arrhythmias, Kato et al. described that AVB 
resolved in 4 of the 7 CS patients by corticosteroid therapy, but did not resolve or improve in 
any of the patients without corticosteroid therapy (Kato et al., 2003). Recently, Banba et al 
evaluated the effect of corticosteroids in CS patients presenting VT or CAVB. In their cohort, 
atrioventricular conduction improved in 5 of 9 CAVB patients after corticosteroid therapy 
albeit the fact that ventricular arrhythmias were not improved after corticosteroid therapy 
(Banba et al., 2007). In regard to ventricular arrhythmias, we evaluated the effect of 
corticosteroids in CS patients presenting VT (Yodogawa et al., 2008). After corticosteroid 
therapy, VT was suppressed in 6 of 15 patients (Responder group). Accumulation of gallium-
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67 was detected more frequently in the responder group than in the non-responder group 
(66.7% vs. 11.1%, p<0.05). All patients underwent SAECG in which the filtered QRS duration 
(f-QRS), the root mean square voltage of the terminal 40 ms (RMS40) in the filtered QRS 
complex and the duration of low-amplitude signals < 40µV (LAS40) in the terminal filtered 
QRS complex were measured. In the responder group, f-QRS and LAS40 were significantly 
decreased and RMS40 was significantly increased compared with those before corticosteroid 
therapy (f-QRS: 136.3+/–30.6msec vs 116.8+/–25.4msec, p<0.05 LAS40: 68.2+/–24.0msec vs 
47.8+/–22.9msec, p<0.05 RMS40: 7.2+/–3.3 msec vs 13.3+/–7.6msec, p<0.05). However, SAECG 
parameters did not change significantly in non-responder group. In addition, we recently 
reported the effect of corticosteroid therapy in CS patients presenting ventricular arrhythmias 
(Yodogawa et al., 2010). The less advanced LV dysfunction patients (EF ≥ 35%) showed 
improvement of ventricular arrhythmias after corticosteroid therapy, and had a significantly 
higher prevalence of Gallium-67 uptake compared with the advanced LV dysfunction patients 
(EF < 35 %). Remission of Gallium-67 uptake was observed in 5 of 6 CS patients after 
corticosteroid therapy. These results suggested that active and reversible inflammation might 
play an important role for the occurrence of ventricular arrhythmias in CS. Thus, CS patients 
with gallium-67 uptake and relatively preserved LV function are thought to be good 
candidates for treatment of the steroid therapy. On the contrary, CS patients with advanced 
LV dysfunction and no gallium-67 uptake are considered to be non-responders to 
corticosteroid therapy, and require earlier initiation of additional therapy such as catheter 
ablation, permanent pacemaker or ICD implantation. In patients with no response to 
corticosteroid therapy or intolerant to steroid side effects, alternative therapy such as 
methotrexate, cyclosporine is the treatment of choice. Although rare, cardiac transplantation 
may be needed for severe CS patients unresponsive to these therapies.  
4. Prognosis 
The prognosis of symptomatic CS is not well elucidated. Although it has been considered 
poor, recent studies have shown better prognosis in patients treated with corticosteroids. 
Yazaki et al. showed 5-year survival rates of 75% in the steroid-treated patients and of 89% 
in patients with a left ventricular ejection fraction > or = 50% (Yazaki et al., 2001). According 
to a report by Chiu et al., survival rate of CS patients was relatively good, at 98% after 1 
year, 93% after 3 years, 90% after 5 years, and 84% after 10 years. Especially, there were no 
cardiac deaths in preserved EF patients (initial LV ejection fractions >55%), during the 
follow-up period of 10 years (Chiu et al., 2005).  Therefore earlier initiation of corticosteroid 
therapy is mandatory for CS patients before the deterioration of cardiac function.  
5. Conclusion  
The early detection of CS is critical for successful treatment and improved prognosis. 
Although MRI and PET scan have renewed the awareness of CS, the early detection still 
remains difficult. Currently, no single test has proven consistently reliable in detecting CS. A 
combination of multiple testing methodologies is considered to be the most reliable 
approach for the early identification. Refinements in noninvasive electrocardiographic 
studies may help in the early detection and management for CS. 
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Sarcoidosis is a type of inflammation that occurs in various locations of the body for no known reason.
Normally, when foreign substances or organisms enter the body, the immune system will fight back by
activating an immune response. Inflammation is a normal part of this immune response, but it should subside
once the foreign antigen is gone. In sarcoidosis, the inflammation persists, and some of the immune cells form
abnormal clumps of tissue called granulomas. The disease can affect any organ in the body, but it is most
likely to occur in the lungs. It can also affect the skin, eyes, liver, or lymph nodes. Although the cause of
sarcoidosis is not known, research suggests that it may be due to an extreme immune response or extreme
sensitivity to certain substances. It also seems to have a genetic component as well, and tends to run in
families. Sarcoidosis most commonly develops in people between 20 and 50 years of age. African Americans
are somewhat more likely to develop sarcoidosis than Caucasians, and females are somewhat more likely to
develop sarcoidosis than males. The symptoms of sarcoidosis depend on the organ involved. This book deals
with the diagnosis and treatment of this mysterious disease of unknown etiology.
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